Livforsakringsbolaget Skandia, Omsesidigt 13F: Adds $2.5M to AMGN Stake

Livforsakringsbolaget Skandia lifted its stake in Amgen Inc. (AMGN) during the third quarter, raising its investment by 5,980 shares. According to a Form 13F filing disclosed with the SEC on October 21, 2026, the firm ended the period with 77,758 shares valued at approximately $32.8 million. That change represents an 8.3% increase over the previous quarter.

AMGN Amgen Inc.

$438.94 ▲ +36.71% year to date

1M 3M YTD

Daily close · Oct 20, 2026

What Changed in Livforsakringsbolaget Skandia's Amgen Position

The fund expanded its position from 71,778 shares up to 77,758 shares. This addition of 5,980 shares brought the total market value of the holding to $32,775,774 as of the filing date.

Other Institutional Activity in Amgen

Other large investors adjusted their positions in Amgen around the same time. Assenagon Asset Management S.A. grew its holdings by 888,819 shares, ending with 1,080,666 shares worth about $455.3 million. Hbw Advisory Services grew its holdings by 2,611 shares, ending with 4,746 shares worth about $2.0 million. Korea Investment lifted its position by 113,743 shares to hold 395,932 shares valued at roughly $140.8 million. Meanwhile, Fort Washington Investment Advisors cut 90,613 shares to finish with 995 shares valued at about $419,402. Curated Wealth Partners trimmed 433,767 shares, leaving it with 1,618 shares worth roughly $682,007.

Amgen Inc. Stock Up 1.6%

Amgen shares recently traded around $438.20, remaining close to the stock's closing price of $438.34 on the day of the filing. The stock sits well above its 200-day moving average of $370.53 and below its 52-week high of $447.03.

Recent Earnings

Amgen reported trailing twelve-month revenue of $38.1 billion alongside a net profit margin of 23.0% and a return on equity of 91.5%. The company posted trailing earnings of $16.10 per share. Investors look ahead to Amgen's next earnings report scheduled for November 3, 2026.

Dividend

The company provides shareholders an annual dividend rate of $10.08 per share, translating to a dividend yield of 2.3%. Amgen maintains a dividend payout ratio of 60.9%, directing a portion of its earnings toward dividend payments.

Insider Buying and Selling at Amgen Inc.

Company insiders executed several transactions prior to the filing. Officer Nancy A. Grygiel sold 2,970 shares on August 6, 2026, at an average price of $402.16 for a total value of $1,194,415. Officer Derek Miller sold 3,890 shares on August 6, 2026, at an average price of $402.54 for a total of $1,565,898. Additionally, officer Rachna Khosla sold 3,252 shares on August 13, 2026, valued at $1,346,499.

Analysts Set New Price Targets

Wall Street firms updated their views on the stock through October. UBS maintains a Buy rating with a target of $470.00 following an update on October 9, 2026. BMO Capital maintains a Market Perform rating with a $415.00 target as of October 12, 2026. Wells Fargo maintains an Equal-Weight rating with a $430.00 target set on October 12, 2026. Guggenheim maintains a Neutral rating with a $378.00 target updated on October 13, 2026. Barclays maintains an Equal-Weight rating with a target of $400.00 on October 21, 2026. Overall, the stock carries a consensus Hold rating and an average price target of $395.67 across 29 analyst opinions.

About Amgen

Based in Thousand Oaks, California, Amgen discovers, develops, manufactures, and delivers human therapeutics worldwide. The company focuses on various medical specialties, including oncology, inflammation, and general medicine, supporting global healthcare providers with advanced biological treatments.

Bottom Line

Livforsakringsbolaget Skandia's increased stake reflects continued institutional interest in the healthcare giant. Investors will watch Amgen's upcoming earnings release on November 3, 2026, for updates on revenue growth and product performance.